Literature DB >> 21422244

The acquisition of antigen cross-presentation function by newly formed dendritic cells.

Priyanka Sathe1, Joanne Pooley, David Vremec, Justine Mintern, Jun-O Jin, Li Wu, Jong-Young Kwak, Jose A Villadangos, Ken Shortman.   

Abstract

The development of Ag-presenting functions by murine dendritic cells (DCs) of the CD8(+) DC lineage was studied using a Flt-3 ligand stimulated bone-marrow culture system. Although newly formed DCs of this lineage are capable of Ag uptake and efficient presentation to T cells on MHC class II, they initially lack the ability to cross-present exogenous Ags on MHC class I. Cross-presentation capacity is acquired as a subsequent maturation step, promoted by cytokines such as GM-CSF. The development of cross-presentation capacity by the DCs in these cultures may be monitored by the parallel development of DC surface expression of CD103. However, the expression of CD103 and cross-presentation capacity are not always linked; therefore, CD103 is not an essential part of the cross-presentation machinery. These results explain the considerable variability in CD103 expression by CD8(+) DCs as well as the findings that not all DCs of this lineage are capable of cross-presentation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21422244     DOI: 10.4049/jimmunol.1002683

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

Review 1.  Mechanisms regulating regional localization of inflammation during CNS autoimmunity.

Authors:  Emily Pierson; Sarah B Simmons; Luca Castelli; Joan M Goverman
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 2.  Dendritic cells in cancer: the role revisited.

Authors:  Filippo Veglia; Dmitry I Gabrilovich
Journal:  Curr Opin Immunol       Date:  2017-02-10       Impact factor: 7.486

Review 3.  The network of cytokines, receptors and transcription factors governing the development of dendritic cell subsets.

Authors:  Priyanka Sathe; Li Wu
Journal:  Protein Cell       Date:  2011-09-09       Impact factor: 14.870

Review 4.  Cross-presentation by dendritic cells.

Authors:  Olivier P Joffre; Elodie Segura; Ariel Savina; Sebastian Amigorena
Journal:  Nat Rev Immunol       Date:  2012-07-13       Impact factor: 53.106

Review 5.  The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting.

Authors:  Miriam Merad; Priyanka Sathe; Julie Helft; Jennifer Miller; Arthur Mortha
Journal:  Annu Rev Immunol       Date:  2013       Impact factor: 28.527

Review 6.  Role of dendritic cell subsets in immunity and their contribution to noninfectious uveitis.

Authors:  Ping Chen; Alastair K Denniston; Sima Hirani; Susan Hannes; Robert B Nussenblatt
Journal:  Surv Ophthalmol       Date:  2015-01-28       Impact factor: 6.048

Review 7.  Combinatorial drug delivery approaches for immunomodulation.

Authors:  Joshua M Stewart; Benjamin G Keselowsky
Journal:  Adv Drug Deliv Rev       Date:  2017-05-19       Impact factor: 15.470

8.  GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells.

Authors:  Melanie Greter; Julie Helft; Andrew Chow; Daigo Hashimoto; Arthur Mortha; Judith Agudo-Cantero; Milena Bogunovic; Emmanuel L Gautier; Jennifer Miller; Marylene Leboeuf; Geming Lu; Costica Aloman; Brian D Brown; Jeffrey W Pollard; Huabao Xiong; Gwendalyn J Randolph; Jerry E Chipuk; Paul S Frenette; Miriam Merad
Journal:  Immunity       Date:  2012-06-29       Impact factor: 31.745

9.  Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells.

Authors:  Haiyan S Li; Chengwen Liu; Yichuan Xiao; Fuliang Chu; Xiaoxuan Liang; Weiyi Peng; Jianhua Hu; Sattva S Neelapu; Shao-Cong Sun; Patrick Hwu; Stephanie S Watowich
Journal:  Sci Signal       Date:  2016-09-27       Impact factor: 8.192

10.  Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.

Authors:  Hélène Salmon; Juliana Idoyaga; Adeeb Rahman; Marylène Leboeuf; Romain Remark; Stefan Jordan; Maria Casanova-Acebes; Makhzuna Khudoynazarova; Judith Agudo; Navpreet Tung; Svetoslav Chakarov; Christina Rivera; Brandon Hogstad; Marcus Bosenberg; Daigo Hashimoto; Sacha Gnjatic; Nina Bhardwaj; Anna Karolina Palucka; Brian D Brown; Joshua Brody; Florent Ginhoux; Miriam Merad
Journal:  Immunity       Date:  2016-04-19       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.